Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027.
PKP2-ACM is an inherited heart muscle condition caused by a change, or variant, in the PKP2 gene.
The clinical-stage genetic medicine company dosed 10 participants, including three in Cohort 1 at a low dose (2×10^13 vg/kg) and seven in Cohorts 2 and 3 at a high dose (6×10^13 vg/kg).
By the October 15, 2026, data cutoff, nine participants reached at least 12 months of follow-up, while one reached nine months.
High-Dose Cohort Cuts Arrhythmias By 80%
In the high-dose group, LX2020 drove an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) from baseline at the latest assessment, with reductions deepening over time and six of seven patients improving.
High-dose treatment also reduced premature ventricular contraction (PVC) burden by a mean of 44%, benefiting five of seven patients.
Five of seven high-dose participants reported symptom improvements on the Patient Global Impression of Change scale, while cardiac MRIs showed stabilized or improved right ventricular function in most high-dose patients.
Cardiac biopsies confirmed dose-dependent increases in LX2020 transduction, exogenous PKP2 mRNA expression, and PKP2 protein expression.
Safety Profile and FDA Regulatory Path
All 10 dosed participants generally tolerated LX2020 well, with no discontinuations or clinically significant complement activation.
Investigators managed previously disclosed liver function test elevations in high-dose patients per protocol without hospitalizations or complications.
One participant experienced a previously disclosed Grade 3 serious adverse event of ventricular tachycardia three months post-dosing, consistent with PKP2-ACM’s natural course.
Doctors treated the patient with anti-arrhythmic medication and discharged them without further intervention.
The FDA expressed openness to guideline-defined NSVT as a primary surrogate endpoint for potential accelerated approval.
Lexeo expects to finalize its pivotal study design, statistical analysis plan, and confirmatory strategy in the first half of 2027 and start the trial in the second half of 2027.
Cash Runway Extends Into 2028
Alongside the trial update, Lexeo reported third-quarter 2026 financial results, holding $219.1 million in cash, cash equivalents, and marketable securities as of September 30, 2026, to fund operations into 2028.
LXEO Price Action: Lexeo Therapeutics shares were up 7.84% at $3.09 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock/ Naeblys
Recent Comments